This study was carried out in association with medical practitioners who were responsible for observing the @entity1 . In a first phase, 58 subjects younger than 70 years with moderate @entity101 were allotted at random to treatment with either @entity7486 (2.5 mg per day) or @entity17132 (20 mg per day). The double blind-double dummy study lasted for six months and demonstrated that the two drugs were similar in efficacy and tolerance. At the end of this phase 42 @entity1 whose supine diastolic blood pressure fell to below 100 mmHg were selected to continue the trial with 20 mg per day @entity17132 in an open long-term study. The survey comprised two periods: the first lasted for six months, the @entity1 being examined every two months, and the second lasted for one year and @entity1 were seen quarterly. However, 8 subjects entered directly into the second period. At each examination standing and supine blood pressure, heart rate and body weight were noted; blood was sampled to allow measurements of serum plasma parameters. Thus 15 @entity1 were treated with @entity17132 over two years and 15 over 18 months. Clinically the fall in blood pressure observed initially was maintained throughout the rest of the trial; but 3 @entity1 needed another drug, i.e. central hypotensor (2 cases) and beta-blocker (1 case). Two subjects complained of transitory cramps, but 3 other complications not imputable to the treatment were observed: one @entity583 and 2 @entity64 . Biologically there was no change in mean plasma @entity972 level, but 3 @entity1 received a @entity972 supplement.(ABSTRACT TRUNCATED AT 250 WORDS)

Treatment of mild to moderate XXXX with @entity17132 . Two years of follow-up.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes'] @entity7486 :: ('MESH:D007190', 'Chemical') :: ['indapamide'] @entity101 :: ('MESH:D006973', 'Disease') :: ['essential hypertension'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity17132 :: ('MESH:D009156', 'Chemical') :: ['muzolimine']
@entity101 :: (MESH:D006973,Disease) :: ['essential hypertension']
